Screener
Polaryx Therapeutics, Inc. PLYX Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Credits | 50 | 19 |
| Capitalized research and development | 998 | 1,217 |
| Total deferred tax assets | 6,642 | 5,332 |
| Valuation allowance | (6,392) | (4,865) |
| Net deferred tax assets | $250 | $467 |
| Deferred tax liabilities | ||
| Accruals and other | (250) | (467) |
| Net deferred tax liabilities | (250) | (467) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s tax credit carryforward valuation allowance?
- Polaryx Therapeutics, Inc. (PLYX) reported tax credit carryforward valuation allowance of $6.39M in Q4 2025.
- What does tax credit carryforward valuation allowance mean?
- This is a contra-asset account that reduces the carrying value of tax credit carryforwards when it is more likely than not that some or all of the credits will not be realized. It reflects management's assessment of the company's ability to generate sufficient future taxable income. A high allowance suggests uncertainty regarding the realization of tax benefits.
Ask your AI about Polaryx Therapeutics, Inc.'s tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude